Ivonescimab continues to demonstrate robust clinical efficacy and safety across multiple Phase III trials, with a strong cash position and no debt supporting ongoing development and commercial preparations. The company anticipates a key FDA decision in November 2026 and is expanding its pipeline and collaborations to address a global market exceeding $100 billion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.